Bleeding risk in breast cancer patients during concomitant administration of warfarin and tamoxifen: A population‐based nested case‐control study | Zendy

Valachis Antonis | Zendy; Garmo Hans | Zendy; Fredriksson Irma | Zendy; Sund Malin | Zendy; Lagerqvist Bo | Zendy; Holmberg Lars | Zendy

Open Access

Bleeding risk in breast cancer patients during concomitant administration of warfarin and tamoxifen: A population‐based nested case‐control study

Author(s) -

Valachis Antonis,

Garmo Hans,

Fredriksson Irma,

Sund Malin,

Lagerqvist Bo,

Holmberg Lars

Publication year - 2020

Publication title -

the breast journal

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.533

H-Index - 72

eISSN - 1524-4741

pISSN - 1075-122X

DOI - 10.1111/tbj.13759

Subject(s) - medicine , tamoxifen , warfarin , odds ratio , breast cancer , nested case control study , concomitant , confidence interval , population , case control study , oncology , gynecology , cancer , environmental health , atrial fibrillation

We aimed to investigate whether the concomitant use of tamoxifen with warfarin is associated with higher risk for bleeding among patients with early estrogen‐receptor (ER)‐positive breast in a population‐based nested case‐control study. We identified 1787 patients taking warfarin and 92 cases hospitalized for bleeding and found an adjusted odds ratio (OR) of 1.42 (95% confidence interval (CI): 0.84‐2.40) for the risk of bleeding in patients treated with warfarin that initiated tamoxifen within the previous 30 days. As a result, we could not definitively rule out a potential association between tamoxifen use during warfarin and bleeding risk in patients with breast cancer.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research